<DOC>
	<DOCNO>NCT00616382</DOCNO>
	<brief_summary>Persistent postnatal ductal patency may significant adverse hemodynamic effect , frequently necessitate therapeutic intervention order facilitate ductal closure . Medical therapy patency ductus arteriosus successful mediating ductal closure approximately 70 % treated infant . In recent study population , 17 % baby show ductal response first course treatment 9.4 % study infant eventually underwent surgical ligation ductus failure medical therapeutic closure.We propose evaluate compare two alternate therapeutic approach ductal closure baby respond initial therapy .</brief_summary>
	<brief_title>Treating Resistant Patent Ductus Arteriosus ( PDA )</brief_title>
	<detailed_description />
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>Inborn premature neonate admit neonatal intensive care unit Shaare Zedek Medical Center diagnose hemodynamically significant patent ductus arteriosus ( sPDA ) consider potential candidate study if/when respond initial therapy Any baby consider viable Any baby IVH grade 34 recent onset ( within 3 day . [ If head ultrasound perform within last 34 day , one perform prior onset study . ] Any baby dysmorphic feature congenital abnormality Any baby structural heart disease PDA Any baby document infection , Any baby thrombocytopenia ( &lt; 50,000 ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Weeks</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>PDA</keyword>
	<keyword>indomethacin</keyword>
	<keyword>pentoxifylline</keyword>
	<keyword>Patent Ductus Arteriosus [ PDA ] resistant therapy</keyword>
</DOC>